TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA CONTRACT MANUFACTURING MARKET 42
1.4 CURRENCY AND PRICING 44
1.5 LIMITATIONS 44
1.6 MARKETS COVERED 44
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 DBMR TRIPOD DATA VALIDATION MODEL 50
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT SEGMENT LIFELINE CURVE 54
2.8 MARKET END USER COVERAGE GRID 55
2.9 DBMR MARKET POSITION GRID 56
2.10 VENDOR SHARE ANALYSIS 57
2.11 SECONDARY SOURCES 58
2.12 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 61
4.1 PESTEL ANALYSIS 64
4.2 PORTER'S FIVE FORCES 65
4.3 STRATEGIC INITIATIVES: 66
5 REGULATORY FRAMEWORK 67
5.1 REGULATORY SCENARIO BY FDA 67
5.2 REGULATORY SCENARIO IN AUSTRALIA 68
5.3 REGULATORY SCENARIO IN EUROPE FOR MEDICINES 69
6 MARKET OVERVIEW 70
6.1 DRIVERS 72
6.1.1 COST-EFFECTIVENESS FOR THE MANUFACTURING COMPANIES 72
6.1.2 RISE OF TECHNOLOGICAL ADVANCEMENTS IN CONTRACT MANUFACTURING 72
6.1.3 MIDDLE EAST & AFRICA PRESENCE AND CONNECTED NETWORK 73
6.2 RESTRAINTS 73
6.2.1 STRINGENT REGULATIONS AMONG VARIOUS JURISDICTIONS 73
6.2.2 RISK OF CONFIDENTIAL INFORMATION 74
6.3 OPPORTUNITIES 74
6.3.1 PATENT EXPIRY AND INCREASING DEMAND FOR GENERIC DRUGS 74
6.3.2 GROWING EXPENSES ON THE DEVELOPMENT OF HEALTHCARE INFRASTRUCTURE 75
6.3.3 INCREASE IN NUMBER OF STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 75
6.4 CHALLENGES 76
6.4.1 INTELLECTUAL PROPERTY RISKS 76
6.4.2 INCREASE IN NUMBER OF PHARMACEUTICAL COMPANIES TO SET UP THEIR MANUFACTURING SITES 76
7 MIDDLE EAST & AFRICA CONTRACT MANUFACTURING MARKET, BY PRODUCT 77
7.1 OVERVIEW 78
7.2 PHARMACEUTICAL PRODUCTS MANUFACTURING 81
7.2.1 TYPES OF PRODUCTS 82
7.2.1.1 TABLETS 82
7.2.1.2 CAPSULES 82
7.2.1.3 BIOLOGICS 83
7.2.1.4 SMALL MOLECULE 83
7.2.1.5 CELL & GENES MANUFACTURING 83
7.2.1.6 NUTRACEUTICALS 83
7.2.1.7 OTHERS 83
7.2.2 TYPE OF SERVICES 83
7.2.2.1 DRUG DEVELOPMENT SERVICES 84
7.2.2.2 TABLET MANUFACTURING SERVICES 84
7.2.2.3 BIOLOGICS API MANUFACTURING 84
7.2.2.4 BIOLOGICS FDF MANUFACTURING SERVICES 84
7.2.2.5 OTHERS 84
7.2.3 BY DOSAGE FORM 84
7.2.3.1 SOLID FORMULATIONS 85
7.2.3.2 LIQUID FORMULATIONS 85
7.2.3.2.1 INJECTABLE 85
7.2.3.2.2 SYRUPS 85
7.2.3.3 SEMI-SOLID FORMULATIONS 85
7.2.3.4 TOPICAL DRUG FORMULATIONS 85
7.2.3.5 OTHERS 85
7.3 MEDICAL DEVICE MANUFACTURING 86
7.3.1 TYPE OF DEVICES 87
7.3.1.1 SYRINGES AND NEEDLES 88
7.3.1.2 INFUSION DEVICES & ADMINISTRATION SETS 88
7.3.1.3 MEDICAL ACCESSORIES, COMPONENTS & CONSUMABLES 88
7.3.1.4 DISPOSABLES 88
7.3.1.5 IVD DEVICES 89
7.3.1.6 CARDIOVASCULAR DEVICES 89
7.3.1.7 DIABETES CARE DEVICES 89
7.3.1.8 GENERAL SURGERY DEVICES 89
7.3.1.9 ORTHOPEDIC DEVICES 89
7.3.1.10 RESPIRATORY DEVICES 89
7.3.1.11 OPHTHALMIC DEVICES 89
7.3.1.12 DENTAL DEVICES 89
7.3.1.13 GYNECOLOGY/UROLOGY DEVICES 89
7.3.1.14 LABORATORY EQUIPMENT 89
7.3.2 TYPE OF SERVICES 90
7.3.2.1 MEDICAL DEVICE DESIGN AND DEVELOPMENT 90
7.3.2.2 DEVICE ASSEMBLY 90
7.3.2.3 REGULATORY ASSISTANCE 90
7.3.2.4 PACKAGING & LABELLING 90
7.3.2.5 STERILIZATION SERVICES 91
7.3.2.6 TRAINING AND VALIDATION 91
7.3.2.7 QUALITY ASSURANCE 91
7.3.2.8 OTHERS 91
7.3.3 BY DEVICE CLASS 91
7.3.3.1 CLASS I MEDICAL DEVICES 92
7.3.3.2 CLASS IIA MEDICAL DEVICES 92
7.3.3.3 CLASS IIB MEDICAL DEVICES 92
7.3.3.4 CLASS III MEDICAL DEVICES 92
8 MIDDLE EAST & AFRICA CONTRACT MANUFACTURING MARKET, BY END USER 93
8.1 OVERVIEW 94
8.2 PHARMACEUTICAL COMPANIES 97
8.3 BIOTECHNOLOGY COMPANIES 97
8.4 BIOPHARMA COMPANIES 98
8.5 MEDICAL DEVICES COMPANIES 99
8.6 ORIGINAL EQUIPMENT MANUFACTURER 99
8.7 RESEARCH INSTITUTES 100
9 MIDDLE EAST & AFRICA CONTRACT MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL 101
9.1 OVERVIEW 102
9.2 RETAIL SALES 105
9.3 DIRECT TENDER 106
9.4 OTHERS 107
10 MIDDLE EAST & AFRICA CONTRACT MANUFACTURING MARKET, BY REGION 108
10.1 MIDDLE EAST AND AFRICA 109
10.1.1 SOUTH AFRICA 122
10.1.2 SAUDI ARABIA 130
10.1.3 U.A.E. 138
10.1.4 EGYPT 146
10.1.5 ISRAEL 154
10.1.6 REST OF MIDDLE EAST AND AFRICA 162
11 MIDDLE EAST & AFRICA CONTRACT MANUFACTURING MARKET: COMPANY LANDSCAPE 163
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 163
12 SWOT ANALYSIS 164
13 COMPANY PROFILE 165
13.1 AENOVA GROUP 165
13.1.1 COMPANY SNAPSHOT 165
13.1.2 COMPANY SHARE ANALYSIS 165
13.1.3 PRODUCT PORTFOLIO 166
13.1.4 RECENT DEVELOPMENTS 166
13.2 THERMO FISHER SCIENTIFIC INC. 167
13.2.1 COMPANY SNAPSHOT 167
13.2.2 REVENUE ANALYSIS 168
13.2.3 COMPANY SHARE ANALYSIS 168
13.2.4 PRODUCT PORTFOLIO 169
13.2.5 RECENT DEVELOPMENTS 169
13.3 EVONIK INDUSTRIES AG 170
13.3.1 COMPANY SNAPSHOT 170
13.3.2 REVENUE ANALYSIS 170
13.3.3 COMPANY SHARE ANALYSIS 171
13.3.4 PRODUCT PORTFOLIO 171
13.3.5 RECENT DEVELOPMENTS 171
13.4 LONZA 172
13.4.1 COMPANY SNAPSHOT 172
13.4.2 REVENUE ANALYSIS 172
13.4.3 COMPANY SHARE ANALYSIS 173
13.4.4 PRODUCT PORTFOLIO 173
13.4.5 RECENT DEVELOPMENTS 174
13.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. 175
13.5.1 COMPANY SNAPSHOT 175
13.5.2 REVENUE ANALYSIS 175
13.5.3 COMPANY SHARE ANALYSIS 176
13.5.4 PRODUCT PORTFOLIO 176
13.5.5 RECENT DEVELOPMENTS 176
13.6 ABBVIE INC. 177
13.6.1 COMPANY SNAPSHOT 177
13.6.2 REVENUE ANALYSIS 177
13.6.3 PRODUCT PORTFOLIO 178
13.6.4 RECENT DEVELOPMENT 178
13.7 ALMAC GROUP 179
13.7.1 COMPANY SNAPSHOT 179
13.7.2 PRODUCT PORTFOLIO 179
13.7.3 RECENT DEVELOPMENTS 179
13.8 AVID BIOSERVICES, INC. 180
13.8.1 COMPANY SNAPSHOT 180
13.8.2 REVENUE ANALYSIS 180
13.8.3 PRODUCT PORTFOLIO 181
13.8.4 RECENT DEVELOPMENT 181
13.9 BAXTER 182
13.9.1 COMPANY SNAPSHOT 182
13.9.2 REVENUE ANALYSIS 182
13.9.3 PRODUCT PORTFOLIO 183
13.9.4 RECENT DEVELOPMENTS 184
13.10 CATALENT, INC 185
13.10.1 COMPANY SNAPSHOT 185
13.10.2 REVENUE ANALYSIS 185
13.10.3 PRODUCT PORTFOLIO 186
13.10.4 RECENT DEVELOPMENT 186
13.11 FAMAR HEALTH CARE SERVICES 187
13.11.1 COMPANY SNAPSHOT 187
13.11.2 PRODUCT PORTFOLIO 187
13.11.3 RECENT DEVELOPMENTS 187
13.12 JUBILANT PHARMA LIMITED 188
13.12.1 COMPANY SNAPSHOT 188
13.12.2 REVENUE ANALYSIS 188
13.12.3 PRODUCT PORTFOLIO 189
13.12.4 RECENT DEVELOPMENT 189
13.13 KIMBALL INTERNATIONAL 190
13.13.1 COMPANY SNAPSHOT 190
13.13.2 REVENUE ANALYSIS 190
13.13.3 PRODUCT PORTFOLIO 191
13.13.4 RECENT DEVELOPMENT 191
13.14 MERCK KGAA 192
13.14.1 COMPANY SNAPSHOT 192
13.14.2 REVENUE ANALYSIS 192
13.14.3 PRODUCT PORTFOLIO 193
13.14.4 RECENT DEVELOPMENTS 193
13.15 NIPR0 194
13.15.1 COMPANY SNAPSHOT 194
13.15.2 REVENUE ANALYSIS 194
13.15.3 PRODUCT PORTFOLIO 195
13.15.4 RECENT DEVELOPMENT 195
13.16 PFIZER INC 196
13.16.1 COMPANY SNAPSHOT 196
13.16.2 REVENUE ANALYSIS 196
13.16.3 PRODUCT PORTFOLIO 197
13.16.4 RECENT DEVELOPMENT 197
13.17 RECIPHARM AB. 198
13.17.1 COMPANY SNAPSHOT 198
13.17.2 REVENUE ANALYSIS 198
13.17.3 PRODUCT PORTFOLIO 199
13.17.4 RECENT DEVELOPMENT 199
13.18 SIEGFRIED HOLDING AG 200
13.18.1 COMPANY SNAPSHOT 200
13.18.2 REVENUE ANALYSIS 200
13.18.3 PRODUCT PORTFOLIO 201
13.18.4 RECENT DEVELOPMENTS 201
13.19 SUN PHARMACEUTICAL INDUSTRIES LTD 202
13.19.1 COMPANY SNAPSHOT 202
13.19.2 REVENUE ANALYSIS 202
13.19.3 PRODUCT PORTFOLIO 203
13.19.4 RECENT DEVELOPMENT 203
13.20 TE CONNECTIVITY 204
13.20.1 COMPANY SNAPSHOT 204
13.20.2 REVENUE ANALYSIS 204
13.20.3 PRODUCT PORTFOLIO 205
13.20.4 RECENT DEVELOPMENT 205
13.21 VETTER PHARMA-FERTIGUNG GMBH & CO. KG 206
13.21.1 COMPANY SNAPSHOT 206
13.21.2 PRODUCT PORTFOLIO 206
13.21.3 RECENT DEVELOPMENTS 206
14 QUESTIONNAIRE 207
15 RELATED REPORTS 210

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.